Mirae Asset Capital is a Seoul-based South Korean investment firm specializing in customized financing solutions. The firm demonstrates a diverse investment strategy, participating in funding rounds from Seed to Series E, with a particular focus on Series B and C investments. Their portfolio spans various sectors including biotechnology, healthcare, artificial intelligence, and technology.
Notable portfolio companies include Apeel Sciences, Insilico Medicine, and Valo Health in the biotech sector, as well as AmazeVR and Syntiant in technology. Mirae Asset Capital's investments range from early-stage startups to more established companies, with total raised amounts for portfolio companies varying widely from $16 million to over $250 million. The firm's global reach is evident in its investments across different geographies and industries.
Mirae Asset Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Total Investments23
Current Portfolio Count20
Total Portfolio Exits0
Top Investment Stages
Series B9 (42.9%)
Series C6 (28.6%)
Series D3 (14.3%)
Series A2 (9.5%)
Seed1 (4.8%)
Stage Mix
Series B 43%Series C 29%Series D 14%Series A 10%Seed 5%
Concentration shown as share of disclosed investments by stage.
Mirae Asset Capital - Classification
- NAICS
- 520000Finance and Insurance
- 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
- 523900Other Financial Investment Activities
- 523990All Other Financial Investment Activities
- 523999Miscellaneous Financial Investment Activities
- SIC
- 6700Holding And Other Investment Offices
- 6720Investment Offices
- 6722Management Investment Offices, Open-end
Show 5 more industry codes
- NAICS
- 525000Funds, Trusts, and Other Financial Vehicles
- 523910Miscellaneous Intermediation
- SIC
- 6000Depository Institutions
- 6790Miscellaneous Investing
- 6799Investors, Not Elsewhere Classified